Partner Headlines - BMY

  1. The Stocks Already in Correction Mode

    FoxBusiness
  2. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  3. Bristol-Myers surprises Street

    IBD
  4. Thursday Morning Earnings Reports

    Benzinga
  5. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  6. Earnings Scheduled For July 24, 2014

    Benzinga
  7. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  8. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  9. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  10. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  11. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  12. Bristol seeks cancer drug nod

    IBD
  13. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  14. Japan approves BMY regimen

    IBD
  15. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  16. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  17. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  18. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  19. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  20. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target ...

    Benzinga
  21. Benzinga's Top Downgrades

    Benzinga
  22. Ex-Dividends For July 1, 2014

    Benzinga
  23. Pfizer and others get EU nods

    IBD
  24. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  25. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  26. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  27. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza ...

    Benzinga
  28. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  29. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  30. BRISTOL-MYERS SQUIBB

    IBD
  31. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab ...

    Benzinga
  32. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  33. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  34. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  35. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  36. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  37. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  38. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  39. Bristol, Merck Q1 sales soft

    IBD
  40. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  41. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, ...

    Benzinga
  42. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  43. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  44. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone ...

    Benzinga
  45. Earnings Scheduled For April 29, 2014

    Benzinga
  46. Stocks To Watch For April 29, 2014

    Benzinga
  47. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  48. Earnings Expectations For The Week Of April 28: Big Oil, Big ...

    Benzinga
  49. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  50. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  51. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  52. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose ...

    Benzinga
  53. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  54. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  55. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  56. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  57. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  58. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  59. Gilead's HCV Challengers Near The Starting Gate

    IBD
  60. Gilead's HCV Challengers Near The Starting Gate

    IBD
  61. Abbott Capturing Incremental Market Share

    GuruFocus
  62. US Stock Futures Jump Ahead Of Economic Data

    Benzinga
  63. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  64. Arrowhead Surges As Analysts Laud Hepatitis B Drug

    IBD
  65. Bristol Moving Ahead With Lung-Cancer Drug Combo

    IBD
  66. Bristol-Myers Squibb's

    IBD
  67. Pfizer Gets Good News For Pneumonia, Bone-Thinner Drugs

    IBD
  68. Market Wrap For February 24: Markets Showing Strength To Start ...

    Benzinga
  69. FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation

    FoxBusiness
  70. Actavis, Forest In $25 Bil Deal

    IBD
  71. Actavis' Buyout Of Forest Creating Spec Pharma Giant

    IBD
  72. Vanguard Health Care Fund's Top Five

    GuruFocus
  73. UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on ...

    Benzinga
  74. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  75. Investors Brace for Bear Market

    FoxBusiness
  76. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  77. #PreMarket Primer: Monday, January 27: Markets Open The Week ...

    Benzinga
  78. Bristol-Myers Int'l Sales Soar

    IBD
  79. Top Earnings-Related Movers for Week of Jan. 20th

    Benzinga
  80. Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

    Benzinga
  81. Bristol Q4 Beats, But Nivolumab Still Worries Market

    IBD
  82. Stocks Open Sharply Lower; Kansas City Southern Collapses

    IBD
  83. Stock Futures Down, Off Lows; Microsoft And Juniper Climb

    IBD
  84. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  85. #PreMarket Primer: Friday, January 24: Growth Fears Drag Down ...

    Benzinga
  86. Earnings Scheduled For January 24, 2014

    Benzinga
  87. Stocks To Watch For January 24, 2014

    Benzinga
  88. Cancer drug result in question

    IBD
  89. Bristol-Myers' New Nivolumab Trial Sparks Worries

    IBD
  90. Growth Fund Of The Year: Stock Picks

    YCharts
  91. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  92. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think ...

    GuruFocus
  93. Ligand Pharmaceuticals Poised For Full-Year Profit

    IBD
  94. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  95. Daclatasvir Marketing Authorization Application for Treatment ...

    Benzinga
  96. The Top Five Drug Launches Of 2013

    IBD
  97. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
  98. New Drugs Could Change Cancer Landscape In 2014

    IBD
  99. Benzinga's Top #PreMarket Losers

    Benzinga
  100. 21 Stocks Giving the Gift of Dividend Growth

    GuruFocus
Trading Center